D
Crescita Therapeutics Inc.
CTX.TO
TSX
D
Sell
11/11/2024Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D- from D on 11/11/2024 due to a substantial decline in the efficiency index, total return index and solvency index. The quick ratio declined from 2.23 to 1.61, net income declined 12.25% from -$676.7 to -$759.6, and total capital declined 5.6% from $13.32M to $12.57M.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D- from D on 11/11/2024 due to a substantial decline in the efficiency index, total return index and solvency index. The quick ratio declined from 2.23 to 1.61, net income declined 12.25% from -$676.7 to -$759.6, and total capital declined 5.6% from $13.32M to $12.57M.
D
Sell
11/13/2023Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from C- on 11/13/2023 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 512.13% from -$168.2 to -$1.03M, net income declined 356.88% from -$209.2 to -$955.8, and earnings per share declined from -$0.0103 to -$0.0469.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from C- on 11/13/2023 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 512.13% from -$168.2 to -$1.03M, net income declined 356.88% from -$209.2 to -$955.8, and earnings per share declined from -$0.0103 to -$0.0469.
C
Hold
11/1/2023Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 11/1/2023 due to a large decline in the volatility index and efficiency index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 11/1/2023 due to a large decline in the volatility index and efficiency index.
C
Hold
8/14/2023Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from C- on 8/14/2023 due to a major increase in the growth index, efficiency index and volatility index. Total revenue increased 12.94% from $3.4M to $3.84M, EBIT increased 3.61% from -$174.5 to -$168.2, and total capital increased 0.54% from $16.53M to $16.62M.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from C- on 8/14/2023 due to a major increase in the growth index, efficiency index and volatility index. Total revenue increased 12.94% from $3.4M to $3.84M, EBIT increased 3.61% from -$174.5 to -$168.2, and total capital increased 0.54% from $16.53M to $16.62M.
C
Hold
8/7/2023Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 8/7/2023 due to a decline in the volatility index, efficiency index and valuation index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 8/7/2023 due to a decline in the volatility index, efficiency index and valuation index.
C
Hold
7/17/2023Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from C- on 7/17/2023 due to an increase in the volatility index and total return index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from C- on 7/17/2023 due to an increase in the volatility index and total return index.
C
Hold
5/24/2023Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 5/24/2023 due to a significant decline in the growth index and total return index. EBIT declined 141.41% from $421.4 to -$174.5, earnings per share declined from $0.0426 to -$0.0099, and total revenue declined 23.41% from $4.44M to $3.4M.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 5/24/2023 due to a significant decline in the growth index and total return index. EBIT declined 141.41% from $421.4 to -$174.5, earnings per share declined from $0.0426 to -$0.0099, and total revenue declined 23.41% from $4.44M to $3.4M.
C
Hold
1/24/2023Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from D+ on 1/24/2023 due to a noticeable increase in the total return index and volatility index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from D+ on 1/24/2023 due to a noticeable increase in the total return index and volatility index.
D
Sell
1/9/2023Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C- on 1/9/2023 due to a noticeable decline in the total return index and valuation index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C- on 1/9/2023 due to a noticeable decline in the total return index and valuation index.
C
Hold
11/16/2022Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C- from D on 11/16/2022 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 615.17% from -$29 to $149.4, earnings per share increased from -$0.0014 to $0.0072, and operating cash flow increased 457.1% from $62.7 to $349.3.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C- from D on 11/16/2022 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 615.17% from -$29 to $149.4, earnings per share increased from -$0.0014 to $0.0072, and operating cash flow increased 457.1% from $62.7 to $349.3.
D
Sell
5/19/2022Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 5/19/2022 due to a decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.0356 to -$0.0179, net income declined 150% from $748.4 to -$374.2, and EBIT declined 135.49% from $836.5 to -$296.9.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 5/19/2022 due to a decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.0356 to -$0.0179, net income declined 150% from $748.4 to -$374.2, and EBIT declined 135.49% from $836.5 to -$296.9.
D
Sell
5/16/2022Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 5/16/2022 due to a noticeable increase in the growth index and volatility index. EBIT increased 204.04% from -$804 to $836.5, earnings per share increased from -$0.0344 to $0.0356, and total revenue increased 152.66% from $2.38M to $6M.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 5/16/2022 due to a noticeable increase in the growth index and volatility index. EBIT increased 204.04% from -$804 to $836.5, earnings per share increased from -$0.0344 to $0.0356, and total revenue increased 152.66% from $2.38M to $6M.
D
Sell
12/21/2021Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 12/21/2021 due to a decline in the total return index, volatility index and valuation index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 12/21/2021 due to a decline in the total return index, volatility index and valuation index.
D
Sell
12/16/2021Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C+ on 12/16/2021 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 23.22% from -$579.7 to -$714.3, earnings per share declined from -$0.0281 to -$0.0344, and total capital declined 4.67% from $18.63M to $17.76M.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C+ on 12/16/2021 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 23.22% from -$579.7 to -$714.3, earnings per share declined from -$0.0281 to -$0.0344, and total capital declined 4.67% from $18.63M to $17.76M.
C
Hold
11/3/2021Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C+ from C on 11/3/2021 due to an increase in the total return index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C+ from C on 11/3/2021 due to an increase in the total return index.
C
Hold
10/13/2021Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C from C+ on 10/13/2021 due to a decline in the volatility index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C from C+ on 10/13/2021 due to a decline in the volatility index.
C
Hold
8/17/2021Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C+ from C on 08/17/2021.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C+ from C on 08/17/2021.
C
Hold
8/12/2021Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from D+ on 8/12/2021 due to a significant increase in the valuation index, growth index and efficiency index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from D+ on 8/12/2021 due to a significant increase in the valuation index, growth index and efficiency index.
D
Sell
5/3/2021Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C- on 5/3/2021 due to a large decline in the total return index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C- on 5/3/2021 due to a large decline in the total return index.
C
Hold
4/16/2021Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C- from D+ on 4/16/2021 due to a substantial increase in the total return index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C- from D+ on 4/16/2021 due to a substantial increase in the total return index.
D
Sell
3/25/2021Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 3/25/2021 due to a substantial increase in the efficiency index, total return index and growth index. Total capital increased 1.12% from $17.34M to $17.53M.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 3/25/2021 due to a substantial increase in the efficiency index, total return index and growth index. Total capital increased 1.12% from $17.34M to $17.53M.
D
Sell
8/13/2020Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 8/13/2020 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0178 to -$0.1083, net income declined 505.74% from -$367.7 to -$2.23M, and EBIT declined 229.4% from -$268.7 to -$885.1.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 8/13/2020 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0178 to -$0.1083, net income declined 505.74% from -$367.7 to -$2.23M, and EBIT declined 229.4% from -$268.7 to -$885.1.
D
Sell
7/6/2020Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 7/6/2020 due to an increase in the valuation index and volatility index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 7/6/2020 due to an increase in the valuation index and volatility index.
D
Sell
6/15/2020Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 6/15/2020 due to a decline in the volatility index and total return index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 6/15/2020 due to a decline in the volatility index and total return index.
D
Sell
5/29/2020Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 5/29/2020 due to an increase in the efficiency index, volatility index and growth index. Operating cash flow increased 402.54% from $39.4 to $198, and EBIT increased 39.48% from -$444 to -$268.7.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 5/29/2020 due to an increase in the efficiency index, volatility index and growth index. Operating cash flow increased 402.54% from $39.4 to $198, and EBIT increased 39.48% from -$444 to -$268.7.
D
Sell
5/15/2020Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 5/15/2020 due to a decline in the valuation index and volatility index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 5/15/2020 due to a decline in the valuation index and volatility index.
D
Sell
4/30/2020Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 4/30/2020 due to an increase in the valuation index and volatility index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 4/30/2020 due to an increase in the valuation index and volatility index.
D
Sell
3/26/2020Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 3/26/2020 due to a large decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.0029 to -$0.0176, net income declined 649.4% from $66.6 to -$365.9, and EBIT declined 222.65% from $362 to -$444.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D from D+ on 3/26/2020 due to a large decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.0029 to -$0.0176, net income declined 649.4% from $66.6 to -$365.9, and EBIT declined 222.65% from $362 to -$444.
D
Sell
3/19/2020Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C- on 3/19/2020 due to a decline in the volatility index and total return index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C- on 3/19/2020 due to a decline in the volatility index and total return index.
C
Hold
3/4/2020Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 3/4/2020 due to a decline in the total return index and volatility index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 3/4/2020 due to a decline in the total return index and volatility index.
C
Hold
2/18/2020Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from C- on 2/18/2020 due to an increase in the efficiency index, total return index and volatility index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from C- on 2/18/2020 due to an increase in the efficiency index, total return index and volatility index.
C
Hold
12/26/2019Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 12/26/2019 due to a noticeable decline in the growth index. Earnings per share declined from $0.0748 to $0.0029, EBIT declined 89.49% from $3.45M to $362, and total revenue declined 46.91% from $7M to $3.72M.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to C- from C on 12/26/2019 due to a noticeable decline in the growth index. Earnings per share declined from $0.0748 to $0.0029, EBIT declined 89.49% from $3.45M to $362, and total revenue declined 46.91% from $7M to $3.72M.
C
Hold
8/13/2019Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from C- on 8/13/2019 due to a noticeable increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0015 to $0.0748, EBIT increased 880.7% from $351.3 to $3.45M, and total revenue increased 118.96% from $3.2M to $7M.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C from C- on 8/13/2019 due to a noticeable increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0015 to $0.0748, EBIT increased 880.7% from $351.3 to $3.45M, and total revenue increased 118.96% from $3.2M to $7M.
C
Hold
6/3/2019Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C- from D+ on 6/3/2019 due to an increase in the volatility index and total return index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C- from D+ on 6/3/2019 due to an increase in the volatility index and total return index.
D
Sell
5/17/2019Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C- on 5/17/2019 due to a large decline in the growth index. Earnings per share declined from $0.1122 to $0.0015, EBIT declined 65.71% from $1.02M to $351.3, and total revenue declined 32.01% from $4.7M to $3.2M.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D+ from C- on 5/17/2019 due to a large decline in the growth index. Earnings per share declined from $0.1122 to $0.0015, EBIT declined 65.71% from $1.02M to $351.3, and total revenue declined 32.01% from $4.7M to $3.2M.
C
Hold
5/1/2019Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C- from D+ on 5/1/2019 due to a noticeable increase in the total return index and volatility index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to C- from D+ on 5/1/2019 due to a noticeable increase in the total return index and volatility index.
D
Sell
3/29/2019Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 3/29/2019 due to a significant increase in the valuation index, efficiency index and growth index. Earnings per share increased from $0.0134 to $0.1122, net income increased 735.25% from $282.3 to $2.36M, and operating cash flow increased 177.64% from -$602.1 to $467.5.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D+ from D on 3/29/2019 due to a significant increase in the valuation index, efficiency index and growth index. Earnings per share increased from $0.0134 to $0.1122, net income increased 735.25% from $282.3 to $2.36M, and operating cash flow increased 177.64% from -$602.1 to $467.5.
D
Sell
11/14/2018Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D from D- on 11/14/2018 due to an increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.0244 to $0.0134, EBIT increased 131.03% from -$1.25M to $388.6, and total revenue increased 90.68% from $1.79M to $3.42M.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D from D- on 11/14/2018 due to an increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.0244 to $0.0134, EBIT increased 131.03% from -$1.25M to $388.6, and total revenue increased 90.68% from $1.79M to $3.42M.
D
Sell
5/10/2018Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D- from D on 5/10/2018 due to a significant decline in the efficiency index, volatility index and total return index.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D- from D on 5/10/2018 due to a significant decline in the efficiency index, volatility index and total return index.
D
Sell
8/16/2017Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D from D- on 8/16/2017 due to a significant increase in the efficiency index and growth index. Total revenue increased 129.95% from $1.57M to $3.61M, EBIT increased 118.22% from -$2.3M to $418.7, and earnings per share increased from -$0.1731 to $0.0267.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D from D- on 8/16/2017 due to a significant increase in the efficiency index and growth index. Total revenue increased 129.95% from $1.57M to $3.61M, EBIT increased 118.22% from -$2.3M to $418.7, and earnings per share increased from -$0.1731 to $0.0267.
D
Sell
7/21/2017Downgrade
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D- from D on 7/21/2017 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 8.99% from $24.69M to $22.48M.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to D- from D on 7/21/2017 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 8.99% from $24.69M to $22.48M.
D
Sell
4/3/2017Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D from D- on 4/3/2017 due to an increase in the valuation index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D from D- on 4/3/2017 due to an increase in the valuation index.
D
Sell
12/1/2016Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D- from E+ on 12/1/2016 due to an increase in the growth index and efficiency index. Total revenue increased 581.67% from $119.5 to $814.6, earnings per share increased from -$0.2081 to -$0.0944, and net income increased 45.08% from -$2.39M to -$1.31M.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to D- from E+ on 12/1/2016 due to an increase in the growth index and efficiency index. Total revenue increased 581.67% from $119.5 to $814.6, earnings per share increased from -$0.2081 to -$0.0944, and net income increased 45.08% from -$2.39M to -$1.31M.
E
Sell
9/1/2016Upgraded
Crescita Therapeutics Inc. (CTX.TO) was upgraded to E+ from E on 9/1/2016 due to a major increase in the volatility index.
Crescita Therapeutics Inc. (CTX.TO) was upgraded to E+ from E on 9/1/2016 due to a major increase in the volatility index.
E
Sell
8/5/2016None
Crescita Therapeutics Inc. (CTX.TO) was downgraded to E from U on 08/05/2016.
Crescita Therapeutics Inc. (CTX.TO) was downgraded to E from U on 08/05/2016.
